1
Clinical Trials associated with Bmab1800 (Biocon Biologics UK Ltd.) / Not yet recruitingPhase 1 A Randomized, Double-blind, Two-arm, Parallel Comparative Multi-center Study to Assess and Compare the Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and Keytruda® as Adjuvant Monotherapy in Patients With Melanoma
The purpose of the study is to evaluate the pharmacokinetic (PK) equivalence of Bmab1800 as compared with reference product Keytruda® in a randomized, double-blind, two-arm, parallel comparative, multi-center study in patients with resected melanoma (Stage IIB, or Stage IIC, or Stage III) as an adjuvant treatment. This study also compares the safety and immunogenicity of Bmab1800 and Keytruda.
100 Clinical Results associated with Bmab1800 (Biocon Biologics UK Ltd.)
100 Translational Medicine associated with Bmab1800 (Biocon Biologics UK Ltd.)
100 Patents (Medical) associated with Bmab1800 (Biocon Biologics UK Ltd.)
100 Deals associated with Bmab1800 (Biocon Biologics UK Ltd.)